Dianthus Therapeutics, Inc. /DE/ (DNTH) insider trading

By person

33 insiders · 121 transactions

10.8×

Marino Garcia holds 10.8 times base salary in stock. $6.82M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Marino Garcia last reported holding, valued at $104.39, the price Common Stock was last bought or sold at on the open market here, on 17 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Marino Garcia

CEO and President

—

$27.96M (12) scheduled

−$27.96M

65,292

0.1167%

$6.82M

—

Ryan Savitz

EVP, CFO & Cbo

—

$14.99M (14) scheduled

−$14.99M

0.0000%

$0.00

—

Simrat Randhawa

EVP, Head of R&D

$52.80K (2)

$15.00M (11) scheduled

−$14.95M

4,000

0.0072%

$417.56K

—

Bruce Booth

Director

$10.00M (1)

$254.42K (1)

+$9.75M

1,250,000

2.23%

$130.49M

—

Edward Carr

Chief Accounting Officer

—

$5.59M (10) scheduled

−$5.59M

0.0000%

$0.00

—

Adam M Veness

SVP, General Counsel and Sec.

—

$4.63M (5) scheduled

−$4.63M

15,000

0.0268%

$1.57M

—

Third Rock Ventures IV, L.P. entity

10% owner

—

$3.06M (2)

−$3.06M

3,058,204

5.47%

$319.25M

+3,061%

Paula Soteropoulos

Director

—

$2.25M (3) scheduled

−$2.25M

0.0000%

$0.00

—

Jason Gardner

See Remarks

$6.00K (1)

$1.79M (8)

−$1.79M

651,964

1.17%

$68.06M

−3.3%

Fairmount Funds Management LLC entity

Director

$1.40M (5)

—

+$1.40M

0.0000%

$0.00

—

Anne McGeorge

Director

—

$844.82K (5) scheduled

−$844.82K

0.0000%

$0.00

—

Michael P. Cooke

Chief Scientific Officer

—

$654.33K (14)

−$654.33K

240,523

0.4300%

$25.11M

−16.7%

Simon Read

Director

—

$630.79K (7) scheduled

−$630.79K

0.0000%

$0.00

—

John C. Davis Jr

See Remarks

—

$508.64K (4) scheduled

−$508.64K

8,304

0.0148%

$866.85K

—

Christina K. Isacson

Chief Business Officer

—

$316.64K (3)

−$316.64K

83,786

0.1498%

$8.75M

−16.7%

Atlas Venture Fund X, L.P. entity

10% owner

—

$254.42K (1)

−$254.42K

3,148,399

5.63%

$328.66M

+3,154%

Zoran Zdraveski

See Remarks

—

$193.45K (2)

−$193.45K

128,009

0.2289%

$13.36M

−5.5%

David Scadden

Director

$99.00K (1)

—

+$99.00K

228,175

0.4079%

$23.82M

+17.9%

Caren Deardorf

Chief Commercial Officer

—

$41.98K (1)

−$41.98K

19,762

0.0353%

$2.06M

—

Thomas W. Beetham

See Remarks

—

$41.07K (1)

−$41.07K

19,897

0.0356%

$2.08M

—

Stephen F. Mahoney

See Remarks

—

$38.60K (1)

−$38.60K

17,264

0.0309%

$1.80M

—

Lisa Olson

See Remarks

—

$38.60K (1)

−$38.60K

14,264

0.0255%

$1.49M

—

Kristen Stants

Chief People Officer

—

$38.60K (1)

−$38.60K

20,264

0.0362%

$2.12M

—

David Wayne Nichols

Chief Technical Officer

—

$38.32K (1)

−$38.32K

14,306

0.0256%

$1.49M

—

Blake Byers

Director

—

3,339,137

5.97%

$348.57M

—

2016 Gp, L.l.c. Gv

10% owner

—

3,339,137

5.97%

$348.57M

—

Lei Meng

Director

—

2,717,554

4.86%

$283.69M

+123.2%

Leon O Moulder Jr

Director

—

1,436,745

2.57%

$149.98M

+13.1%

Amy L Ronneberg

Director

—

593,611

1.06%

$61.97M

—

Michael W Bonney

Director

—

215,346

0.3850%

$22.48M

+11.3%

Thomas O Daniel

Director

—

101,926

0.1822%

$10.64M

+31.7%

Jeffrey W. Albers

Director

—

4,152

0.0074%

$433.43K

—

Alexis Borisy

Director

—

4,100

0.0073%

$428.00K

—

Dianthus Therapeutics, Inc.

What the insiders did Net buying

By person